0001567619-21-004527.txt : 20210219
0001567619-21-004527.hdr.sgml : 20210219
20210219191851
ACCESSION NUMBER: 0001567619-21-004527
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210204
FILED AS OF DATE: 20210219
DATE AS OF CHANGE: 20210219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rhodes Jennifer J
CENTRAL INDEX KEY: 0001568249
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39990
FILM NUMBER: 21657801
MAIL ADDRESS:
STREET 1: C/O ADAMAS PHARMACEUTICALS INC.
STREET 2: 1900 POWELL ST., SUITE 750
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Angion Biomedica Corp.
CENTRAL INDEX KEY: 0001601485
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113430072
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 51 CHARLES LINDBERGH BOULEVARD
CITY: UNIONDALE
STATE: NY
ZIP: 11553
BUSINESS PHONE: (415) 655-4899
MAIL ADDRESS:
STREET 1: 51 CHARLES LINDBERGH BOULEVARD
CITY: UNIONDALE
STATE: NY
ZIP: 11553
3/A
1
doc1.xml
FORM 3/A
X0206
3/A
2021-02-04
2021-02-04
0
0001601485
Angion Biomedica Corp.
ANGN
0001568249
Rhodes Jennifer J
C/O ANGION BIOMEDICA CORP.
51 CHARLES LINDBERGH BLVD.
UNIONDALE
NY
11553
0
1
0
0
See Remarks
Common Stock
35242
D
Stock Option (Right to Buy)
9.52
2030-02-13
Common Stock
116687
D
Stock Option (Right to Buy)
7.78
2030-06-17
Common Stock
58343
D
Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.
25% of the total shares subject to the option shall vest on the first anniversary measured from January 13, 2020 (the "Vesting Commencement Date") and 1/24th of the shares subject to the option will vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date.
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from June 18, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Amendment made to reflect updated Beneficial Ownership after RSU vesting on January 13, 2021 not previously reflected.
/s/ Jennifer J. Rhodes
2021-02-19